Climb Bio (NASDAQ:CLYM - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Climb Bio to post earnings of ($0.15) per share for the quarter.
Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Climb Bio Stock Performance
Shares of CLYM opened at $1.27 on Wednesday. The stock has a market cap of $85.82 million, a price-to-earnings ratio of -0.60 and a beta of -0.12. The company's fifty day moving average is $1.27. Climb Bio has a 1-year low of $1.05 and a 1-year high of $9.58.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
